Verrica Pharmaceuticals Inc (VRCA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.45 (-4.30%), Market cap $0.10B, 52-week low–high $0.49 ~ $9.10.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration a
Financial statements, price targets, institutional (13F) holdings and related news for Verrica Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Verrica Pharmaceuticals Inc trades at $4.45 (-4.30%). Real-time quotes and charts are available on BlackAll Trade.
Verrica Pharmaceuticals Inc has a market cap of about $0.10B.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The c